Piramal Pharma Balance Sheet Health
Financial Health criteria checks 2/6
Piramal Pharma has a total shareholder equity of ₹77.6B and total debt of ₹45.3B, which brings its debt-to-equity ratio to 58.5%. Its total assets and total liabilities are ₹147.8B and ₹70.2B respectively. Piramal Pharma's EBIT is ₹3.5B making its interest coverage ratio 0.8. It has cash and short-term investments of ₹6.0B.
Key information
58.5%
Debt to equity ratio
₹45.34b
Debt
| Interest coverage ratio | 0.8x |
| Cash | ₹5.95b |
| Equity | ₹77.58b |
| Total liabilities | ₹70.18b |
| Total assets | ₹147.76b |
Recent financial health updates
No updates
Recent updates
It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)
Mar 26
Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Feb 28Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161
Feb 02Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Nov 09Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Aug 11Financial Position Analysis
Short Term Liabilities: PPLPHARMA's short term assets (₹49.5B) exceed its short term liabilities (₹36.0B).
Long Term Liabilities: PPLPHARMA's short term assets (₹49.5B) exceed its long term liabilities (₹34.2B).
Debt to Equity History and Analysis
Debt Level: PPLPHARMA's net debt to equity ratio (50.8%) is considered high.
Reducing Debt: Insufficient data to determine if PPLPHARMA's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: PPLPHARMA's debt is not well covered by operating cash flow (19.1%).
Interest Coverage: PPLPHARMA's interest payments on its debt are not well covered by EBIT (0.8x coverage).